Available Clinical Trials
Displaying All Clinical Trials (62)
A011401
Randomized Phase III Trial Evaluating the Role of Weight Loss …
Randomized Phase III Trial Evaluating the Role of Weight Loss …
A011502
Alliance A11502 - Aspirin in Preventing Recurrence of Cancer in Patients …
Alliance A11502 - Aspirin in Preventing Recurrence of Cancer in Patients …
A021502
Alliance A021502 - Randomized Trial of Standard Chemotherapy Alone or …
Alliance A021502 - Randomized Trial of Standard Chemotherapy Alone or …
A031102
A031102 – A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy …
A031102 – A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy …
A031501
A031501 - Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) …
A031501 - Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) …
A031704
Alliance A031704 - “PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab …
Alliance A031704 - “PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab …
A041501
A041501 - A Phase III Trial to Evaluate the Efficacy …
A041501 - A Phase III Trial to Evaluate the Efficacy …
A041701
A041701 - A Randomized Phase II/III Study of Conventional Chemotherapy …
A041701 - A Randomized Phase II/III Study of Conventional Chemotherapy …
A041702
A041702 - A Randomized Phase III Study of Ibrutinib Plus …
A041702 - A Randomized Phase III Study of Ibrutinib Plus …
A051301
A051301 - A randomized double-blind phase III study of ibrutinib …
A051301 - A randomized double-blind phase III study of ibrutinib …
A051701
A051701 - Randomized phase II/III study of venetoclax (ABT 199) …
A051701 - Randomized phase II/III study of venetoclax (ABT 199) …
A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo …
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo …
A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). …
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). …
A221505
A221505 - RT CHARM: Phase III Randomized Trial of Hypofractionated …
A221505 - RT CHARM: Phase III Randomized Trial of Hypofractionated …
AGCT1531
AGCT1531: A Phase 3 Study of Active Surveillance for Low …
AGCT1531: A Phase 3 Study of Active Surveillance for Low …
Apollomics APL 101-01
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, …
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, …
BMS CA209-592
An Exploratory Study of the Biologic Effects and Biomarkers of …
An Exploratory Study of the Biologic Effects and Biomarkers of …
BMS CA209-592
An Exploratory Study of the Biologic Effects and Biomarkers of …
An Exploratory Study of the Biologic Effects and Biomarkers of …
BMS CA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
BMS CA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
CCTG MA.39
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer …
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer …
Daiichi Sankyo DS8201-A-U303
A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, …
A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, …
E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage …
A Phase III Double-Blind Trial for Surgically Resected Early Stage …
EA1131
Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. …
Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. …
EA3161
EA3161 - A Phase II/III Randomized Study of Maintenance Nivolumab …
EA3161 - A Phase II/III Randomized Study of Maintenance Nivolumab …
EA4151
EA4151 - A Randomized Phase III Trial of Consolidation with …
EA4151 - A Randomized Phase III Trial of Consolidation with …
EA6134
EA6134 - A Randomized Phase III Trial of Dabrafenib + …
EA6134 - A Randomized Phase III Trial of Dabrafenib + …
EA8143
EA8143 – A Phase 3 RandOmized Study Comparing PERioperative Nivolumab …
EA8143 – A Phase 3 RandOmized Study Comparing PERioperative Nivolumab …
EA9131
EA9131 - A Simplified Patient Care Strategy to Decrease Early …
EA9131 - A Simplified Patient Care Strategy to Decrease Early …
EA9161
EA9161 - A Randomized Phase III Study of the Addition …
EA9161 - A Randomized Phase III Study of the Addition …
EAQ162CD
EAQ162CD - Longitudinal Assessment of Financial Burden in Patients with …
EAQ162CD - Longitudinal Assessment of Financial Burden in Patients with …
ECOG EA2182
EA2182, A Randomized Phase II Study of De-intensified Chemoradiation for …
EA2182, A Randomized Phase II Study of De-intensified Chemoradiation for …
Exact Sciences 2018-01
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated …
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated …
Exact Sciences 2018-02
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated …
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated …
Galera GTI 4419-301
ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – …
ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – …
Galera GTI-4419-203
A Phase 2A Open-Label Trial of the Effects of Intravenous …
A Phase 2A Open-Label Trial of the Effects of Intravenous …
Genmab GCT1015-05
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy …
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy …
GIT 4419-203
A Phase 2a Open-Label Trial of the Effects of Intravenous …
A Phase 2a Open-Label Trial of the Effects of Intravenous …
GOG 0263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation …
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation …
Infinity IPI 549 02
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate …
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate …
Merck MK3475-667
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) …
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) …
Merck MK3475-966
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus …
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus …
NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
The National Myelodysplastic Syndromes (MDS) Study
NRG BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin …
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin …
NRG GY005
NRG GY005 - A Randomized Phase II/III study of the …
NRG GY005 - A Randomized Phase II/III study of the …
NRG-CC004
NRG-CC004 - Phase II Double Blind Dose Finding Trial of …
NRG-CC004 - Phase II Double Blind Dose Finding Trial of …
NRG-GI004 / SWOG-S1610
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized …
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized …
NRG-GU002
NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen …
NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen …
NRG-GU007
NRG-GU007, Randomized Phase II Trial of Niraparib with Standard Combination …
NRG-GU007, Randomized Phase II Trial of Niraparib with Standard Combination …
NRG-GY018
NRG-GY018 - A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab …
NRG-GY018 - A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab …
NRG-LU002
NRG-LU002 - Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation …
NRG-LU002 - Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation …
NSABP B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and …
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and …
PUMA NER-5201
AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH …
AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH …
QUILT 2.023
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF N-803, A FUSION …
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF N-803, A FUSION …
QUILT 3.055
A Phase 2b, Single-Arm, Multicohort, Open-Label Study of ALT-803 in …
A Phase 2b, Single-Arm, Multicohort, Open-Label Study of ALT-803 in …
S1418
SWOG S1418 - A Randomized, Phase III Trial to Evaluate …
SWOG S1418 - A Randomized, Phase III Trial to Evaluate …
S1616
S1616 - A Phase II Randomized Study of Nivolumab (NSC-748726) …
S1616 - A Phase II Randomized Study of Nivolumab (NSC-748726) …
S1801
S1801 - A Phase II Randomized Study of Adjuvant Versus …
S1801 - A Phase II Randomized Study of Adjuvant Versus …
S1815
S1815 - A Phase III Randomized Trial of Gemcitabine, Cisplatin, …
S1815 - A Phase III Randomized Trial of Gemcitabine, Cisplatin, …
SWOG S1714
S1714 - A Prospective Observational Cohort Study to Develop a …
S1714 - A Prospective Observational Cohort Study to Develop a …
SWOG S1826
S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) …
S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) …
Takeda Ponatinib-3001
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus …
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus …
Appointments Available
Request an appointment
Schedule Now
Information Hotline
Have a question? Call us at:
(864) 603-6200
